Dulcoflex® 5mg tablets For constipation
India’s No.1 brand for constipation
Find gentle relief from constipation overnight with just one Dulcoflex® tablet before bed, helping stimulate bowel movements and soften stools within just 6 to 8 hours.
• Relief within 6 to 8 hours
• Gentle on your bowels
• Non-habit forming laxative
Where to buy
Why choose Dulcoflex®
For constipation
Provides overnight
relief
Is non-habit
forming
Helps improve
bowel movement
What’s inside
Bisacodyl I.P. 5mg
Dulcoflex® tablets and suppositories contain a single active ingredient, Bisacodyl I.P. 5mg, which plays a vital role in delivering effective constipation relief. By stimulating bowel muscles and softening stools, it facilitates easier passage and delivers effective relief.
How does it work
Dulcoflex® is a stimulant laxative that helps manage constipation. Its active ingredient—Biacasodyl stimulates bowel muscles, helping you pass stools and providing relief from constipation.
Directions for use
Dulcoflex® 5mg tablets for constipation
Note : Consult your physician for personalised instructions and additional guidance based on your specific condition.
Real Relief
Learn how reclaiming control over your digestive well-being looks like
Frequently asked questions
Dulcoflex® is a laxative that provides gentle relief in 6 to 8 hours. It functions by stimulating the movement of the intestines, allowing for a smooth passage of stool. Additionally, it is used to thoroughly cleanse the intestines prior to medical procedures and examinations.
It is recommended to take Dulcoflex® before bedtime, as it takes 6 to 8 hours for the medication to effectively work. By taking it before sleeping, you allow sufficient time for the medication to work overnight and pass stools in the morning.
It is important to follow the instructions provided by your physician when taking Dulcoflex® 5mg tablets. In general, the recommended dosage for adults is 1-2 tablets, which should be taken at bedtime. However, it is crucial to consult your doctor for personalised advice based on your specific condition and medical history.
Yes, Dulcoflex® is a brand recommended by doctors across India, to manage constipation.
Similar to other laxatives, Dulcoflex® tablets are not typically recommended for daily, long-term use. It is advisable to avoid taking Dulcoflex® on a daily basis for an extended period of time.
There are no adequate and well-controlled studies in pregnant women. Long experience has shown no evidence of undesirable or damaging effects during pregnancy. Nevertheless, as with all drugs, DULCOFLEX® should be taken during pregnancy only on medical advice. Bisacodyl is not distributed into breast milk. Can be used during lactation. Talk to your doctor before taking Dulcoflex if you are pregnant, planning to become pregnant or are breast feeding.
Tell your doctor if you are taking, have recently taken or might take any other medicines. This is because Dulcoflex can affect the way some other medicines work. Also, some other medicines can affect the way Dulcoflex work. In particular, tell your doctor if you are taking:
a) Diuretics
b) Steroid
c) Other laxative medicines
Dulcoflex can be consumed by pediatric population > 4 years of age and adult population. Children aged 10 years or younger with chronic or persistent constipation should only be treated under the guidance of a physician.
For more information, visit www.sanofi.in
References
1. IMS MAT April’23
2. Prescribing Information for Bisacodyl CCDS V1 dated 23rd Apr 2020 sanofi.in/dam/jcr:659be037-3aa9-4c23-bd9d-2791888f9539/Dulcoflex PI_Sep 2021.pdf Accessed on 23rd June 2023
3. National Center for Biotechnology Information. PubChem Compound Summary for CID 2391, Bisacodyl. https://pubchem.ncbi.nlm.nih.gov/compound/Bisacodyl.
4. Levine, Jules, and Seymour H. Rinzler. "Comparison of laxative action of bisacodyl suppositories and glycerin suppositories in acute myocardial infarction∗." The American journal of cardiology 5.1 (1960): 108-110.
5. Wald, A. Is chronic use of stimulant laxatives harmful to the colon? J.Cpn.Gastroenterol. 2003; 36(5):386-389.
6. Wald, A. Constipation in the primary care setting: current concepts and misconceptions. Am.J.Med. 2006; 119(9):736-739.
7. Muller-pssner, S. A. et. al. Myths and misconceptions about chronic constipation. Am.J.Gastroenterol. 2005; 100(1):232-242.
8. Nelson AD, Camilleri M, Chirapongsathorn S, Vijayvargiya P, Valentin N, Shin A, Erwin PJ, Wang Z, Murad MH. Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis. Gut. 2017 Sep;66(9):1611-1622. doi: 10.1136/gutjnl-2016-311835. Epub 2016 Jun 10.
9. Kienzle-Horn, S. et. al. Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-bpnd, randomized, placebo-controlled study. Apment.Pharmacol.Ther. 2006; 23(10):1479-1488.
10. Kienzle-Horn S, Vix JM, Schuijt C, Peil H, Jordan CC, Kamm MA. Comparison of bisacodyl and sodium picosulphate in the treatment of chronic constipation. Curr Med Res Opin. 2007 Apr;23(4):691-9. doi: 10.1185/030079907x178865.
11. Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S; American Gastroenterological Association Institute Cpnical Guidepnes Committee. American Gastroenterological Association Institute Guidepne on the Medical Management of Opioid-Induced Constipation. Gastroenterology. 2019 Jan;156(1):218-226. doi: 10.1053/j.gastro.2018.07.016.PMID30340754
12. Package Insert